Center of Research on Obesity and Cardiovascular Disease

肥胖与心血管疾病研究中心

• 批准号: 10225369
• 负责人: Lisa A Cassis
• 金额: $ 114.75万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10225369
• 关键词: Adipose tissue; Advisory Committees; Aging; Alzheimer' s Disease; Area; Award; Basic Science; Body Composition; Cardiovascular Diseases; Cardiovascular system; Center for Translational Science Activities; Centers of Research Excellence; Chronic Disease; Clinical Research; Clinical Sciences; Core Facility; Death Rate; Development; Diabetes Mellitus; Disease; Equipment; Etiology; Evaluation; Extramural Activities; Fostering; Funding; Gills; Goals; Growth; High Prevalence; Hypertension; Infrastructure; Institutes; Institution; Kentucky; Limb structure; Link; Lipids; Malignant Neoplasms; Mass Spectrum Analysis; Mentors; Morphology; Mus; Neurodegenerative Disorders; Neurosciences; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pathology; Phase; Physicians; Pilot Projects; Prevalence; Publications; Publishing; Request for Applications; Research; Research Infrastructure; Research Personnel; Research Support; Risk; Risk Factors; Scientist; Services; Strategic Planning; System; Technology; Tissues; Translating; Translational Research; United States National Institutes of Health; Universities; cancer research center director; cardiovascular risk factor; clinical care; clinical center; comorbidity; dietary; energy balance; experience; health disparity; human disease; improved; lipidomics; obesity development; programs; research facility; small molecule; success; targeted treatment; therapy development; voucher

Phase III of the Center for Biomedical Research Excellence (COBRE) on Obesity and Cardiovascular Diseases (COCVD) will further develop and expand upon obesity as an underlying risk factor for the development of cardiovascular diseases, type 2 diabetes, cancer and neurodegenerative diseases. Each of these diseases are rampant in Kentucky, and obesity has been identified as a contributing risk factor for each condition. For Phase III of the COCVD, we will transition the research core facilities developed during Phase I and II of this program to independence. We will also support pilot project studies that include obesity as a risk factor for disease development. We have experienced considerable success, having supported 23 junior investigators and 21 pilot project investigators who generated $52 million in extramural funding and published more than 500 scholarly publications. Collectively, our team has published more than 280 scholarly articles that directly cite COCVD support. We developed an analytical core that provides services in lipidomics and other small molecules, a pathology core that provides specialized services to quantify adipose and other tissue morphology, and an energy balance and body composition core that is not duplicated in capacity across the institution or the Commonwealth. During Phase III of the COCVD, we will transition each core to self- sustaining capacity and upgrade core equipment and use by continuing to provide high quality specialized services, and by expanding core capabilities through provision of additional services that relate obesity to other diseases (e.g., cancer). Transition to independence of COCVD cores will be facilitated by use of a voucher system to promote core use. We will also continue our strong tradition of pilot project funding, which will be expanded to include studies that focus on obesity as an underlying risk factor for not only cardiovascular diseases, but also type 2 diabetes, cancer and neurodegenerative diseases. These areas have been designated as areas of strength across the institution (as each disease is a health disparity experienced by Kentuckians), and are designated for growth within a new research facility that will focus on Kentucky's health disparities. The Administrative Core will oversee all administrative functions of the COCVD and in conjunction with the Program Coordinator and the Scientific Internal Advisory Committee will serve as the operational limb of the Center. An External Advisory Committee, composed of experts in related fields, will provide ongoing assessment and evaluation of the Center. Institutional commitment continues to be outstanding and is supplemented by strong evidence of programmatic growth of direct relevance to this Phase III COCVD.

肥胖和心血管疾病生物医学研究卓越中心（COBRE）的第三阶段 疾病（COCVD）将进一步发展和扩大肥胖作为潜在的危险因素， 心血管疾病、2型糖尿病、癌症和神经退行性疾病的发展。中的每 这些疾病在肯塔基州十分猖獗，而肥胖已被确定为每种疾病的危险因素 条件至于核心研究计划第三期，我们会把第一期发展的核心研究设施， 和第二个独立的计划。我们还将支持包括肥胖风险在内的试点项目研究 疾病发展的因素。我们已经取得了相当大的成功， 研究人员和21名试点项目研究人员，他们获得了5200万美元的校外资金，并发表了 500多篇学术论文。我们的团队总共发表了280多篇学术文章 直接引用COCVD支持。我们开发了一个分析核心，提供脂质组学服务， 其他小分子，病理学核心，提供量化脂肪和其他组织的专业服务 形态，以及能量平衡和身体组成核心，在整个 机构或联邦。在COCVD的第三阶段，我们将把每一个核心都转换为自我， 通过继续提供高质量的专业化服务， 服务，并通过提供与肥胖相关的其他服务来扩大核心能力， 疾病（例如，癌症）。使用代金券将促进COCVD核心向独立性的过渡 系统，以促进核心的使用。我们还将继续我们的试点项目资助的强大传统，这将是 扩展到包括关注肥胖的研究，肥胖不仅是心血管疾病的潜在危险因素， 糖尿病、癌症和神经退行性疾病。这些地区 被指定为整个机构的优势领域（因为每种疾病都是 肯塔基州），并指定在一个新的研究机构，将重点放在肯塔基州的健康增长 差距。行政核心将监督COCVD的所有行政职能， 与计划协调员和科学内部咨询委员会将作为业务分支 的中心。一个由相关领域专家组成的外部咨询委员会将不断提供 对中心进行评估和评价。机构的承诺仍然没有兑现， 并辅以与第三阶段COCVD直接相关的方案增长的有力证据。